Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial. This is an ASCO ...

Bipolar transurethral resection represents a significant evolution in the surgical management of bladder cancer, particularly for non‐muscle invasive bladder cancer (NMIBC). This technique utilises an ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Richard T. Bryan, PhD, Wenyu Liu, PhD, Sarah J. Pirrie, MSc, Rashid Amir, FRCR, Jean Gallagher, Ana I. Hughes, MSc, Kieran P. Jefferson, FRCS, Allen Knight, MBA ...

The BladderPath study showed mpMRI reduced TTCT by 45 days for MIBC patients, enhancing treatment efficiency without harming non-MIBC patients. Conducted in 17 UK hospitals, the study involved 143 ...

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...

Analysis of Tumor Microenvironmental Features Between Primary and Synchronous Liver Metastases From Patients With Colorectal Cancers Using a Deep Learning Algorithm We present an automated tumor risk ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

There are different stages of bladder cancer depending on how the tumor has spread. The staging of bladder cancer can help a medical professional map out the best treatment plan and improve a person’s ...